Professor Drummond said this integrated approach to research translation was central to the collaboration’s success.
“This collaboration represents one of the most effective examples of a research translation pathways that I’ve seen in the Australian higher education sector,” he said.
“By bringing clinicians, researchers and industry partners together from day one, Professor Bansal and the team have shown how universities can work with industry to drive impact faster, at scale, and on a global stage.”
The collaboration has grown from an initial AU$400,000 industry investment into more than AU$17.5 million in combined project value, supported by the Cooperative Research Centres Projects (CRC‑P) and other Commonwealth-supported programs. It has also supported Nexsen's progression to an ASX-listed company (ASX: NXN), established ISO 13485‑aligned MedTech manufacturing capability at RMIT, and built a 40‑plus strong multidisciplinary workforce spanning academia, healthcare and industry.
By integrating discovery research with clinical, regulatory and commercial pathways from the outset, the RMIT-Nexsen partnership has created a platform for new diagnostic products beyond GBS, including applications in neonatal sepsis, renal disease, biosecurity and agricultural health. The collaboration is now engaging with international health organisations to support global deployment, particularly in low‑ and middle‑income countries.
Professor Drummond said the impact of the work is envisaged to be felt well beyond the life of the initial project.
“We’re incredibly proud of Professor Bansal, the RMIT team, and our partners at Nexsen,” Professor Drummond said.
“Their work is not only improving maternal and neonatal health outcomes but is also establishing a repeatable model for industry–research collaboration that will support future generations of Australian innovation.”